Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA) is a late clinical-stage biopharmaceutical company based in the Seattle, Washington area, dedicated to developing small molecule therapeutics aimed at restoring neuronal health and slowing neurodegeneration. Athira's innovative pipeline includes several promising compounds, particularly targeting the neurotrophic hepatocyte growth factor (HGF) system, which plays a crucial role in nervous system maintenance and repair.
The company’s lead candidate, Fosgonimeton (ATH-1017), is a subcutaneously administered small molecule designed to positively modulate the HGF/MET system. It is currently being evaluated in the Phase 2/3 LIFT-AD clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, with topline data expected in the second half of 2024. Fosgonimeton has shown potential in enhancing neuroprotective, neurotrophic, and anti-inflammatory pathways, which are critical in combating neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
In addition to Fosgonimeton, Athira’s pipeline includes ATH-1105 and ATH-1020, both designed to be orally available treatments enhancing the HGF/MET system. ATH-1105 is particularly promising in preclinical models of amyotrophic lateral sclerosis (ALS), demonstrating significant neuroprotective effects, enhanced survival, and improved motor and nerve functions. The company plans to initiate first-in-human studies for ATH-1105 in the first half of 2024.
Athira's research is bolstered by funding from notable organizations such as the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, and Dolby Family Ventures. This support underscores the company’s strong financial position and its capacity to advance its therapeutic candidates through key development milestones.
Recent updates highlight the therapeutic potential of Athira’s small molecules. For instance, fosgonimeton has demonstrated promising results in preclinical models of Alzheimer’s and Parkinson’s diseases, showing neuroprotective effects and improvement in cognitive and motor functions. Additionally, ATH-1105's preclinical studies have shown consistent beneficial effects in ALS models, reinforcing Athira’s approach and commitment to developing novel therapies for neurodegenerative diseases.
Athira is also active in the scientific community, regularly presenting its findings at major conferences and publishing in peer-reviewed journals. The company’s efforts are focused on leveraging its patented technologies to develop cost-effective treatments that address the root causes of neurodegenerative diseases, setting it apart from competitors that primarily target disease symptoms.
For more information about Athira Pharma, Inc., visit www.athira.com and follow the company on Facebook, LinkedIn, X (formerly known as Twitter), and Instagram.
Athira Pharma has announced a public offering of 4,000,000 shares of common stock at a price of $22.50 per share, aiming to raise gross proceeds of $90 million. The offering is expected to close on January 25, 2021, pending standard closing conditions. Athira has also granted underwriters a 30-day option to purchase an additional 600,000 shares. The offering is being managed by Goldman Sachs, Jefferies, and Stifel, with a registration statement that became effective on January 20, 2021. The proceeds will support the company’s efforts in developing therapies for neurodegeneration.
Athira Pharma has launched an underwritten public offering of 4,000,000 shares of its common stock, with an additional option for underwriters to purchase 600,000 more shares. The offering will be conducted by Goldman Sachs, Jefferies, and Stifel as joint book-running managers. The offering is subject to market conditions and the registration statement is pending effectiveness. This move aims to raise capital for ongoing development efforts in restoring neuronal health and combating neurodegeneration. Further details are accessible via the underwriters.
Athira Pharma, a late clinical-stage biopharmaceutical company listed on NASDAQ under the symbol ATHA, announced that its President and CEO, Leen Kawas, Ph.D., will present at the 39th Annual J.P. Morgan Conference on January 14, 2021, at 2:50 p.m. ET. The presentation will focus on the company's pipeline and innovations aimed at restoring neuronal health and combating neurodegeneration.
A live webcast will be available on the company's investor website, with an archived replay accessible for 90 days post-presentation.
Athira Pharma (NASDAQ: ATHA) announced the appointment of Kelly A. Romano to its Board of Directors. Romano, founder of BlueRipple Capital, brings over 30 years of experience in technology and operations, previously serving at United Technologies Corp. Her addition aims to support Athira's goal of advancing ATH-1017 for Alzheimer’s disease in clinical trials. Athira’s efforts focus on developing treatments that restore neuronal health, with promising clinical data for ATH-1017 noted. The company emphasizes ongoing commitment to patient care in neurodegenerative diseases.
Athira Pharma (NASDAQ: ATHA) has received a $15 million research grant from the National Institute on Aging to support the ACT-AD Phase 2 clinical trial for its lead candidate, ATH-1017, targeting mild-to-moderate Alzheimer's disease. This grant emphasizes the federal commitment to advancing innovative research in cognitive health. The ACT-AD trial will assess ATH-1017's impact on cognitive functions using quantitative EEG and other metrics. ATH-1017 aims to enhance brain health by targeting Hepatocyte Growth Factor and its receptor, MET.
Athira Pharma (NASDAQ: ATHA) has initiated patient dosing in the Phase 2 ACT-AD clinical trial, focusing on its drug ATH-1017 for mild-to-moderate Alzheimer’s disease. This randomized, placebo-controlled study will enroll around 75 participants across the US and Australia, evaluating cognitive improvements over 26 weeks. The trial aims to use EEG measures to assess brain function, building on previous data from the LIFT-AD trial. Athira aims to leverage this innovative approach to advance their treatment options for Alzheimer’s and potentially other dementias.
Athira Pharma (NASDAQ: ATHA) announced significant developments in their LIFT-AD clinical trial for ATH-1017, focusing on mild-to-moderate Alzheimer’s disease. The trial is actively enrolling patients, and dosing has commenced. As of September 30, 2020, the company reported a robust cash position of $259.9 million, a notable increase from $85.2 million in June 2020. R&D expenses rose to $5.8 million due to clinical trial preparations, while G&A expenses increased to $1.6 million. The net loss for Q3 2020 was $8.5 million, or $1.12 per share.
Athira Pharma (NASDAQ: ATHA), a clinical-stage biopharmaceutical company, announced participation by Dr. Leen Kawas and Dr. Hans Moebius in upcoming investor conferences. They will present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, and at the Jefferies Virtual London Healthcare Conference on November 19, 2020. Live webcasts of both events will be available through the Athira website, with archived replays accessible for 90 days after the presentations. Athira focuses on developing small molecules aimed at restoring neuronal health and treating neurodegenerative diseases.
Athira Pharma (NASDAQ: ATHA) is hosting a webinar on October 28 at 1 p.m. PT to discuss the P300 testing method's role in assessing cognitive functioning related to Alzheimer's disease. Featured speakers include Larry Ereshefsky and Leen Kawas, who will delve into the P300 latency measurement and its links to cognitive outcomes in patients undergoing ATH-1017 treatment. The event will be accessible via Athira's investor website, with a replay available for 30 days post-event.
Lumen Bioscience announced the appointment of Mark Litton, PhD, MBA, Chief Operating Officer of Athira Pharma (NASDAQ: ATHA), to its Board of Directors. With over two decades in life sciences, including experience as co-founder and Chief Business Officer at Alder BioPharmaceuticals, Dr. Litton brings valuable expertise in strategic growth and financing. Lumen is focused on developing biologic drugs for diseases lacking effective treatments, utilizing innovative drug development technologies aimed at reducing costs and improving access.
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
What is Athira Pharma, Inc.?
What are Athira's lead compounds?
What is the focus of Athira's research?
When are the next significant milestones for Athira?
Who funds Athira's research?
What differentiates Athira's approach from other companies?
What is Fosgonimeton?
What recent achievements has Athira reported?
How does Athira contribute to the scientific community?
Where can I find more information about Athira Pharma?
